Impact of additive on vaccine response

Article

A recent study offers hope for more effective vaccine responses.

A universal influenza vaccine has long been a goal for researchers and an Emory Vaccine Center study may have found some possibilities that could pave the way to one in the future.

Researchers found that adding an additive called AS03, which was an adjuvant, would enhance the response to the vaccine. Following exposure to the additive, both naïve and non-naïve immune cells worked more efficiently in the presence of a virus. Other research had shown that the immune system would produce a wider array of antibodies when exposed to an unknown influenza virus.

The results have also spurred questions on whether the adjuvant could help improve results of COVID-19 vaccines. Adjuvant AS03 has been offered by manufacturer GlaxoSmithKline to be used in COVID-19 vaccine trials.

For more on the findings, check out our sister publication Drug Topics.

Newsletter

Access practical, evidence-based guidance to support better care for our youngest patients. Join our email list for the latest clinical updates.

Recent Videos
Potential downstream benefits of RSV preventive measures, with Octavio Ramilo, MD
Contemporary Pediatrics: RX Review: Updates and Unmet Need in RSV thumbnail
Contemporary Pediatrics: RX Review: Updates and Unmet Need in RSV thumbnail
Contemporary Pediatrics: RX Review: Updates and Unmet Need in RSV thumbnail
Staphylococcus aureus risk in infants and neonatologist considerations with Aaron Milstone, MD
Octavio Ramilo, MD, reacts to the FDA approval of clesrovimab for RSV prevention | Image Credit: St. Jude Children's Research Hospital
Tina Tan, MD, comments on FDA expanded approval for MenQuadfi meningococcal disease vaccine
Tina Tan, MD, discusses impact of FDA's stricter COVID-19 vaccine policy for children
Related Content
© 2025 MJH Life Sciences

All rights reserved.